Grail Shares Plunge 50% as Clinical Trial Failure Overshadows Q4 Earnings Beat

Shares of Grail (GRAL) plummeted by 50% in premarket trading on Friday following the failure of a major cancer screening trial. While the biotech firm reported fourth-quarter financial results that exceeded market expectations, the positive earnings were completely overshadowed by the disappointing clinical outcome. The company's flagship three-year trial failed to meet its primary objective, marking a significant setback for its multi-cancer early detection technology. Investors reacted sharply to the clinical news, prioritizing long-term product viability over short-term financial performance. Analysts suggest that the failure raises critical questions about the company's regulatory path and future commercial prospects. Consequently, the market is undergoing a fundamental re-evaluation of Grail's valuation despite its recent quarterly beat.